Patidistrogene bexoparvovec

贝哌替基

Report date: 2024/12/19 14:08:48

Base Information

Drug NamePatidistrogene bexoparvovec
Drug Alias NamescAAVrh74-tMCK-hSGCAscAAVrh74.tMCK.hSGCAMYO-102SRP-9004
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh74 vector
Mechanisms of ActionAlpha-sarcoglycan gene transference
TargetsAlpha-sarcoglycan
Therapy Area/IndicationsSarcoglycanopathiesMuscular Dystrophies, Limb-GirdleMuscular Dystrophies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNationwide Children'S HospitalMyonexus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSarepta Therapeutics IncNationwide Children'S Hospital
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophies, Limb-Girdle
Inactive IndicationsSarcoglycanopathiesMuscular Dystrophies

Other Information

ATC CodeN/A
Related LinksN/A